ASMB
Assembly Biosciences, Inc.Healthcare · $410M market cap
Verdict
We can't put a fair value on ASMB right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow ASMB
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 30, 2026: no open-market purchases, 8 sales worth $238K and 5 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Okazaki Jason A
CEO and President · 2026-11-02
Sold
$1K
Okazaki Jason A
CEO and President · 2026-11-02
Sold
$120K
Gaggar Anuj
Chief Medical Officer · 2026-11-02
Sold
$590
Gaggar Anuj
Chief Medical Officer · 2026-11-02
Sold
$50K
White Nicole S
Chief Manufacturing Officer · 2026-11-02
Sold
$590
Other filings
Okazaki Jason A
CEO and President · 2026-10-30
Award
38,380 shares
Gaggar Anuj
Chief Medical Officer · 2026-10-30
Award
13,705 shares
Delaney William E IV
Chief Scientific Officer · 2026-10-30
Award
13,705 shares
White Nicole S
Chief Manufacturing Officer · 2026-10-30
Award
13,705 shares
Bjorkquist Jeanette M
PFO and PAO · 2026-10-30
Award
3,840 shares
Questions about ASMB
Are insiders buying ASMB?
Since Oct 30, 2026: no open-market purchases, 8 sales worth $238K and 5 other filings (stock awards, tax withholding and similar).
How can I check ASMB's value myself?
Use the free Sticker Price calculator, already filled with ASMB's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 3, 2026. How the Payback Price works